http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2554459-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b8d67cf351de858c042b9001fa180ca |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-341 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2012-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_427e053b9f86d0d44f6e106315718108 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_888c4e7cd96bb95c57cf903395ce5c7e |
| publicationDate | 2015-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2554459-T3 |
| titleOfInvention | Combined therapy with interferon beta and andrographolides for multiple sclerosis |
| abstract | A compound of Formula I: ** Formula ** wherein R1 is selected from the group consisting of hydrogen, alkyl, or hydroxyl, R2 is selected from the group consisting of hydroxyalkyl or alkyl-O-L1, where L1 is a residue of carbohydrate, R3 is selected from the group consisting of hydrogen or hydroxyl, X is selected from the group consisting of C (> = CH2), CH (OH), or a residue of spirooxirane-2. Z is selected from the group consisting of CH2, CH (OH), or C (> = O), and R4 is selected from the group consisting of an optionally substituted L2-alkyl or L2-alkenyl, wherein L2 is a 3- moiety optionally substituted furanyl or an optionally substituted 3-fur-3-enyl moiety, or a pharmaceutically acceptable salt, ester, ether or prodrug thereof, for use in treating a demyelinating disease in a human patient wherein said demyelinating disease comprises the multiple sclerosis and where said human patient is treated with beta interferon. |
| priorityDate | 2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.